Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Radiopharm Theranostics / Equity Bottom-Up

<ul><li>Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.</li><li>Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets identified through precision oncology & validated by clinical trials & regulatory approval.</li><li>RAD101, an F-18 radioisotope developed to image brain metastases is the most advanced asset.</li></ul>

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets identified through precision oncology & validated by clinical trials & regulatory approval.RAD101, an F-18 radioisotope developed to image brain metastases is the most advanced asset.

<ul><li>Zacks Small-Cap Research Note for Radiopharm Theranostics Limited (RADX)</li></ul>

Zacks Small-Cap Research Note for Radiopharm Theranostics Limited (RADX)

RADX: Interim Readout Achieves 92% Concordance

<ul><li>Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.</li><li>Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets originated by precision oncology & validated by clinical trials & regulatory approval.</li><li>RAD101, an 18F radioisotope developed to image brain metastases is the most advanced asset.</li></ul>

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets originated by precision oncology & validated by clinical trials & regulatory approval.RAD101, an 18F radioisotope developed to image brain metastases is the most advanced asset.

United States

Radiopharm Theranostics Limited operates as a biotech company. The Company focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. Radiopharm Theranostics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Radiopharm Theranostics (RADX US)

RADX: Fiscal 3Q:26 Cash Flow Report

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

RADX: RAD 101 Phase IIb Interim Analysis

Zacks Small-Cap Research Note for Radiopharm Theranostics Limited (RADX)

Zacks Small Cap Research

RADX: 1H:26 Cash Flow & Program Update

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

RADX: Interim Readout Achieves 92% Concordance

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

RADX: Program and Financial Updates

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)